Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system

被引：18

作者：

Fujisawa, Yasuhiro ^{[1
,2
,3
]}

Yoshikawa, Shusuke ^{[1
,4
]}

Minagawa, Akane ^{[1
,5
]}

Takenouchi, Tatsuya ^{[1
,6
]}

Yokota, Kenji ^{[1
,7
]}

Uchi, Hiroshi ^{[1
,8
]}

Noma, Naoki ^{[1
,9
]}

Nakamura, Yasuhiro ^{[1
,10
]}

Asai, Jun ^{[1
,11
]}

Kato, Junji ^{[1
,12
]}

Fujiwara, Susumu ^{[1
,13
]}

Fukushima, Satoshi ^{[1
,14
]}

Uehara, Jiro ^{[1
,15
]}

Hoashi, Toshihiko ^{[1
,16
]}

Kaji, Tatsuya ^{[1
,17
]}

Fujimura, Taku ^{[1
,18
]}

Namikawa, Kenjiro ^{[1
,19
]}

Yoshioka, Manabu ^{[1
,20
]}

Murata, Naoki ^{[1
,21
]}

Ogata, Dai ^{[1
,22
]}

Matsuyama, Kanako ^{[1
,23
]}

Hatta, Naohito ^{[1
,24
]}

Shibayama, Yoshitsugu ^{[1
,25
]}

Fujiyama, Toshiharu ^{[1
,26
]}

Ishikawa, Masashi ^{[1
,27
]}

Yamada, Daisuke ^{[1
,28
]}

Kishi, Akiko ^{[29
]}

Nakamura, Yoshiyuki ^{[3
]}

Shimiauchi, Takatoshi ^{[2
,26
]}

Fujii, Kazuyasu ^{[2
,30
]}

Fujimoto, Manabu ^{[3
]}

Ihn, Hironobu ^{[2
,14
]}

Katoh, Norito ^{[2
,11
]}

机构：

[1] Japanese Melanoma Study Grp, Fukuoka, Fukuoka, Japan

[2] Japanese Skin Canc Soc, Prognosis & Stat Invest Comm, Hamamatsu, Shizuoka, Japan

[3] Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki, Japan

[4] Shizuoka Canc Ctr, Dept Dermatol, Nagaizumi, Shizuoka, Japan

[5] Shinshu Univ, Sch Med, Dept Dermatol, Matsumoto, Nagano, Japan

[6] Niigata Canc Ctr, Dept Dermatol, Niigata, Japan

[7] Nagoya Univ, Dept Dermatol, Nagoya, Aichi, Japan

[8] Univ Kyushu, Dept Dermatol, Fukuoka, Fukuoka, Japan

[9] Osaka City Univ, Dept Dermatol, Osaka, Japan

[10] Saitama Med Univ Int Med Ctr, Dept Dermatol, Hidaka, Saitama, Japan

[11] Kyoto Prefectural Univ Med, Dept Dermatol, Kyoto, Japan

[12] Sapporo Med Univ, Dept Dermatol, Sapporo, Hokkaido, Japan

[13] Kobe Univ, Dept Dermatol, Kobe, Hyogo, Japan

[14] Kumamoto Univ, Dept Dept Dermatol & Plast Surg, Kumamoto, Japan

[15] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan

[16] Nippon Med Sch, Dept Dermatol, Tokyo, Japan

[17] Okayama Univ, Grad Sch Med, Dept Dermatol, Okayama, Japan

[18] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan

[19] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[20] Univ Occupat Environm Hlth, Dept Dermatol, Kitakyushu, Fukuoka, Japan

[21] Univ Hokkaido, Dept Plast Surg, Sapporo, Hokkaido, Japan

[22] Saitama Med Univ, Dept Dermatol, Saitama, Japan

[23] Univ Gifu, Dept Dermatol, Gifu, Japan

[24] Toyama Prefectural Cent Hosp, Dept Dermatol, Toyama, Japan

[25] Fukuoka Univ, Dept Dermatol, Fukuoka, Fukuoka, Japan

[26] Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka, Japan

[27] Saitama Prefectural Canc Ctr, Dept Dermatol, Saitama, Japan

[28] Univ Tokyo, Dept Dermatol, Tokyo, Japan

[29] Toranomon Gen Hosp, Dept Dermatol, Tokyo, Japan

[30] Kagoshima Univ, Dept Dermatol, Kagoshima, Japan

来源：

JOURNAL OF DERMATOLOGICAL SCIENCE | 2019年 / 94卷 / 02期

关键词：

Melanoma; Epidemiology; MALIGNANT-MELANOMA; IPILIMUMAB; SURVIVAL;

D O I：

10.1016/j.jdermsci.2019.04.003

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: The American Joint Committee on Cancer (AJCC) 8th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. Objective: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. Methods: The AJCC 7th and 8th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8th staging were selected. The Kaplan-Meier method was used to estimate disease-specific survival and relapse-free survival. Results: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7th and 8th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/ 94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7th and 8th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA= 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID= none/6.5%. Conclusion: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7th and 8th Edition systems, we should be careful in managing Stage Ill disease since the survival curves of the 8th Edition staging were completely different from the 7th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively. (C) 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.

引用

页码：284 / 289

页数：6

共 12 条

[1]

[Anonymous], 2018, NIVOLUMAB TREATING P

[2] THE INCIDENCE, PREVALENCE, AND SURVIVAL OF MALIGNANT MELANOMA IN TAIWAN [J].

Chang, H. Y. ;

Feng, H. L. ;

Wang, L. ;

Chou, P. ;

Wang, P. F. .

VALUE IN HEALTH, 2014, 17 (07) :A740-A740

[3] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].

Eggermont, A. M. M. ;

Chiarion-Sileni, V. ;

Grob, J. -J. ;

Dummer, R. ;

Wolchok, J. D. ;

Schmidt, H. ;

Hamid, O. ;

Robert, C. ;

Ascierto, P. A. ;

Richards, J. M. ;

Lebbe, C. ;

Ferraresi, V. ;

Smylie, M. ;

Weber, J. S. ;

Maio, M. ;

Bastholt, L. ;

Mortier, L. ;

Thomas, L. ;

Tahir, S. ;

Hauschild, A. ;

Hassel, J. C. ;

Hodi, F. S. ;

Taitt, C. ;

de Pril, V. ;

de Schaetzen, G. ;

Suciu, S. ;

Testori, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855

[4] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].

Eggermont, Alexander M. M. ;

Blank, Christian U. ;

Mandala, Mario ;

Long, Georgina, V ;

Atkinson, Victoria ;

Dalle, Stephane ;

Haydon, Andrew ;

Lichinitser, Mikhail ;

Khattak, Adnan ;

Carlino, Matteo S. ;

Sandhu, Shahneen ;

Larkin, James ;

Puig, Susana ;

Ascierto, Paolo A. ;

Rutkowski, Piotr ;

Schadendorf, Dirk ;

Koornstra, Rutger ;

Hernandez-Aya, Leonel ;

Maio, Michele ;

van den Eertwegh, Alfonsus J. M. ;

Grob, Jean-Jacques ;

Gutzmer, Ralf ;

Jamal, Rahima ;

Lorigan, Paul ;

Ibrahim, Nageatte ;

Marreaud, Sandrine ;

van Akkooi, Alexander C. J. ;

Suciu, Stefan ;

Robert, Caroline .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801

[5] Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma [J].

Fujisawa, Yasuhiro ;

Yoshikawa, Shusuke ;

Minagawa, Akane ;

Takenouchi, Tatsuya ;

Yokota, Kenji ;

Uchi, Hiroshi ;

Noma, Naoki ;

Nakamura, Yasuhiro ;

Asai, Jun ;

Kato, Jiinji ;

Fujiwara, Susumu ;

Fukushima, Satoshi ;

Uehara, Jiro ;

Hoashi, Toshihiko ;

Kaji, Tatsuya ;

Fujimura, Taku ;

Namikawa, Kenjiro ;

Yoshioka, Manabu ;

Murao, Naoki ;

Ogata, Dai ;

Matsuyama, Kanako ;

Hatta, Naohito ;

Shibayama, Yoshitsugu ;

Fujiyama, Toshiharu ;

Ishikawa, Masashi ;

Yamada, Daisuke ;

Kishi, Akiko ;

Nakamura, Yoshiyuki ;

Shimiauchi, Takatoshi ;

Fujii, Kazuyasu ;

Fujimoto, Manabu ;

Ihn, Hironobu ;

Katoh, Norito .

CANCER MEDICINE, 2019, 8 (05) :2146-2156

[6] Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual [J].

Gershenwald, Jeffrey E. ;

Scolyer, Richard A. ;

Hess, Kenneth R. ;

Sondak, Vernon K. ;

Long, Georgina V. ;

Ross, Merrick I. ;

Lazar, Alexander J. ;

Faries, Mark B. ;

Kirkwood, John M. ;

McArthur, Grant A. ;

Haydu, Lauren E. ;

Eggermont, Alexander M. M. ;

Flaherty, Keith T. ;

Balch, Charles M. ;

Thompson, John F. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :472-492

[7] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update [J].

Ishihara, Kazuyuki ;

Saida, Toshiaki ;

Otsuka, Fujio ;

Yamazaki, Naoya .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (01) :33-41

[8]

Ishihara Kazuyuki, 2001, International Journal of Clinical Oncology, V6, P109

[9] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma [J].

Long, G. V. ;

Hauschild, A. ;

Santinami, M. ;

Atkinson, V. ;

Mandala, M. ;

Chiarion-Sileni, V. ;

Larkin, J. ;

Nyakas, M. ;

Dutriaux, C. ;

Haydon, A. ;

Robert, C. ;

Mortier, L. ;

Schachter, J. ;

Schadendorf, D. ;

Lesimple, T. ;

Plummer, R. ;

Ji, R. ;

Zhang, P. ;

Mookerjee, B. ;

Legos, J. ;

Kefford, R. ;

Dummer, R. ;

Kirkwood, J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1813-1823

[10] Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients [J].

Teramoto, Y. ;

Keim, U. ;

Gesierich, A. ;

Schuler, G. ;

Fiedler, E. ;

Tueting, T. ;

Ulrich, C. ;

Wollina, U. ;

Hassel, J. C. ;

Gutzmer, R. ;

Goerdt, S. ;

Zouboulis, C. ;

Leiter, U. ;

Eigentler, T. K. ;

Garbe, C. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) :443-451

← 1 2 →